H. S. Rho et al. / Bioorg. Med. Chem. Lett. 19 (2009) 1532–1533
1533
detected (respectively, IC50 = 12.47
l
M and IC50 = 9.82
l
M). N-
OH
OH
OAc
OAc
a
b, c
Adamantyl-3,4-dihydroxy benzamide 6d showed a better inhibi-
tory activity (IC50 = 1.25 M). Among all the derivatives tested,
compound 6e containing 2,3-dihydroxyl groups exhibited stronger
inhibitory activity (IC50 = 0.73 M). Its activity was about five
times more potent than that of hydroquinone (IC50 = 3.97 M).
HO
HO
l
O
O
3a = 2,4-OH
3b = 3,5-OH
3c = 2,5-OH
3d = 3,4-OH
3e = 2,3-OH
l
4a = 2,4-OAc
4b = 3,5-OAc
4c = 2,5-OAc
4d = 3,4-OAc
4e = 2,3-OAc
l
Although five dihydroxyl benzamide derivatives (6a–e) had no
tyrosinase inhibitory activities, there were potent depigmenting
activities in cell based assay. Inhibition pathways of 6a–e may be
different from those of compound 1 and 4-n-butyl resorcinol. From
these result, compound 6d and 6e can be considered as a good can-
didate for depigmenting agent because their activities were more
potent than that of hydroquinone known to be the most powerful
depigmenting agent. Further studies on their depigmenting mech-
anism are underway in our laboratory.
OH
OH
OAc
OAc
H
H
N
d
N
O
O
6a = 2,4-OH
6b = 3,5-OH
6c = 2,5-OH
6d = 3,4-OH
6e = 2,3-OH
5a = 2,4-OAc
5b = 3,5-OAc
5c = 2,5-OAc
5d = 3,4-OAc
5e = 2,3-OAc
References and notes
Scheme 2. Reaction conditions: (a) acetic anhydride, Et3N, DMAP (cat), THF; (b)
ethylchloroformate, N-methylmorpholine, THF; (c) adamantamine.HCl, Et3N, DMF
(d) (d) KOH, H2O.
1. Spritz, R. A.; Hearing, V. J. Adv. Hum. Genet. 1994, 22, 1.
2. Marmol, V. D.; Beermann, F. FEBS Lett. 1996, 381, 165.
3. (a) Khatib, S.; Nerya, O.; Musa, R.; Shumuel, M.; Tamir, S.; Vaya, J. Bioorg. Med.
Chem. 2005, 13, 433; (b) Shimizu, K.; Kondo, R.; Sakai, K.; Takeda, N.; Nagahata,
T.; Oniki, T. Lipids 2001, 36, 1321; (c) Shimizu, K.; Kondo, R.; Sakai, K. Planta
Med. 2000, 66, 11; (d) Nerya, O.; Vaya, J.; Musa, R.; Izrael, S.; Ben-Arie, R.; Tamir,
S. J. Agric. Food Chem. 2003, 51, 1201.
acted immediately adamantamine.HCl to produce the correspond-
ing amide derivatives (5a–e). The hydrolysis of compounds (5a–e)
afforded desired final products, dihydroxyl benzamides (6a–e).8
Above six synthesized compounds were evaluated for mush-
room tyrosinase activity9 and their ability to inhibit melanin for-
mation by a murine melanocytes cell line (Melan-a).10 Their
activities were compared with 4-n-butyl resorcinol and hydroqui-
none (Table 1).
4. Kim, D. S.; Kim, S. Y.; Park, S. H.; Choi, Y. G.; Kwon, S. B.; Kim, M. K.; Na, J. I.;
Youn, S. W.; Park, K. C. Biol. Pharm. Bull. 2005, 12, 2216.
5. (a) Rho, H. S.; Baek, H. S.; Lee, B. S.; Kim, J. H.; Kim, D. H.; Chang, I. S. Bull. Korean
Chem. Soc. 2006, 27, 115; (b) Baek, H. S.; Rho, H. S.; Yoo, J. W.; Ahn, S. M.; Lee, J.
Y.; Lee, J.; Kim, M. K.; Chang, I. S. Bull. Korean Chem. Soc. 2008, 29, 43.
6. Compound 1: 1H NMR (300 MHz, DMSO-d6): d 8.98 (s, 1H), 8.89 (s, 1H), 6.80 (d,
1H, J = 8.4 Hz), 6.22 (s, 1H), 6.10 (d, 1H, J = 8.4 Hz), 1.99 (s, 9H), 1.69 (s, 6H). IR
vmax (KBr) 3486, 3390, 2903, 1614 cmÀ1. FABMS: (m/e) 259 [M+H]+.
7. Shokova, E.; Tafeenko, V.; Kovalev, V. Tetrahedron Lett. 2002, 43, 5153.
8. We previous reported dihydroxyl benzamide derivatives 6a–6e on Korean
Patent 0,643,514, 2005 and 0,740,575, 2007. Compound 6a: 1H NMR (300 MHz,
DMSO-d6): d 12.62 (s, 1H), 10.07 (s, 1H), 7.73 (d, 1H, J = 8.7 Hz), 7.65 (s, 1H),
6.21 (m, 2H), 2.05 (s, 9H), 1.65 (s, 6H). IR vmax (KBr) 3429, 3221, 2904, 1650,
1583 cmÀ1. FABMS: (m/e) 302 [M+H]+. Compound 6b: 1H NMR (300 MHz,
DMSO-d6): d 9.36 (s, 2H), 7.34 (s, 1H), 6.57 (s, 2H), 6.29 (s, 1H), 2.02 (s, 9H), 1.63
(s, 6H). IR vmax (KBr) 3430, 3221, 2907, 1652, 1584 cmÀ1. FABMS: (m/e) 302
[M+H]+. Compound 6c: 1H NMR (300 MHz, DMSO-d6): d 11.14 (s, 1H), 8.93 (s,
1H), 8.04 (s, 1H), 7.26 (s, 1H), 6.71 (m, 2H), 2.05 (s, 9H), 1.65 (s, 6H). IR vmax
Consistent with previous reports, 4-n-butyl resorcinol induced a
strong inhibition of the tyrosianse activity (IC50 = 0.15
strong activity was also detected in melan-a cells
(IC50 = 21.64 M). When the n-butyl group was replaced by ada-
mantane moiety, the resulting compound 1 showed slightly lower
tyrosinase inhibitory activity (IC50 = 0.90 M) but more potent
depigmenting activity (IC50 = 8.82 M) in cell based assay. These
lM). Its
l
l
l
results indicate that adamantane group enhances the tyrosinase
inhibitory activity and cell penetration of resorcinol like n-butyl
group. Encouraged by this result, we synthesized five dihydroxyl
benzamide derivatives containing adamantane moiety and evalu-
ated their activities. Dihydroxy benzoic acids were conjugated with
adamantamine. Surprisingly, in tyrosinase assay, N-adamantyl-2,4-
dihydroxy benzamide 6a showed no inhibitory activity
(KBr) 3429, 3222, 2905, 1651, 1580 cmÀ1
.
FABMS: (m/e) 302 [M+H]+.
Compound 6d: 1H NMR (300 MHz, DMSO-d6): d 9.18 (bs, 1H), 9.02 (bs, 1H),
7.19 (s, 1H), 7.17 (s, 1H), 7.10 (d, 1H, J = 8.1 Hz), 6.71 (d, 1H, J = 8.1 Hz). 2.03 (s,
9H), 1.63 (s, 6H). IR vmax (KBr) 3428, 3220, 2903, 1650, 1582 cmÀ1. FABMS: (m/
e) 302 [M+H]+. Compound 6e: 1H NMR (300 MHz, DMSO-d6): d 12.20 (s, 1H),
9.21 (s, 1H), 7.92 (s, 1H), 7.33 (d, 1H, J = 1.5 Hz), 6.89 (d, 1H, J = 1.5 Hz), 6.64 (m,
1H), 2.07 (s, 9H), 1.65 (s, 6H). IR vmax (KBr) 3427, 3223, 2901, 1650, 1580 cmÀ1
.
FABMS: (m/e) 302 [M+H]+.
9. Measurements of mushroom tyrosinase activity: Mushroom tyrosinase,
tyrosine were purchased from Sigma Chemical. The reaction mixture for
mushroom tyrosinase activity consisted of 150 l of 0.1 M phosphate buffer
(pH 6.5), 3 l of sample solution, 8 l of mushroom tyrosinase (2100 U/ml,
0.05 M phosphate buffer at pH 6.5), and 36 l of 1.5 mM -tyrosine. Tyrosinase
activity was determined by reading the optical density at 490 nm on
L-
(IC50 > 200 lM). All other derivatives (6b, 6c, 6d and 6e), having
different dihydroxyl positions, also showed no inhibitory activities.
Introduction of amide linkage caused a negative influence on the
binding to tyrosinase. However, unexpected results were obtained
in melan-a cells. Compound 6a exhibited potent depigmenting
activity (IC50 = 34.15 lM). When 3,5-dihydroxyl, and 2,5-dihydr-
oxyl derivatives (6b and 6c) were tested, increased activities were
l
l
l
l
L
a
microplate reader (Bio-Rad 3550, Richnmond, CA, U.S.A.) after incubation for
20 min at 37 °C. The inhibitory activity of the sample was expressed as the
concentration that inhibits 50% of the enzyme activity (IC50).
10. Measurements of melanin content and cell viability: Melanin content and cell
number were measured in melan-a melanocytes. Murine melan-a melanocytes
were originally derived from C57BL/6 J (black, a/a) mice, a kind gift from Prof.
Dorothy C. Bennett (St. George’s Hospital, London, U.K.). The melanin content
Table 1
Depigmenting activities of 4-n-butyl resorcinol and diphenolic compounds containing
adamantane moiety 1 and 6a–6e
was measured using the method reported by Hosoi et al. with
a slight
modification.11 The cells (2 Â 105 cells/ml) were seeded into 24-well plates and
the test compounds were added in triplicate. The medium was changed daily
and after 4 d of culture, the cells were lysed with 1 ml of 1 N NaOH. Then
a
a
Compound
Tyrosinase IC50
M)
Pigmentation IC50
(lM)
% Survival of melan-
a cell
(
l
200 ll of each crude cell extract was transferred into 96-well plates. The
4-n-Butyl
0.15
21.64
98.21 (80
l
M)
relative melanin content was measured at 400 nm with a microplate reader
(Molecular Devices). Cell viability was determined using a modified crystal
violet assay.12 After removing the medium from each well, the cells were
washed with PBS and stained with 0.1% crystal violet in 10% ethanol for 5 min
at room temperature. The cells were then rinsed four times with distilled
water, and crystal violet retained by adherent cells was extracted with 95%
ethanol at room temperature for 10 min. Crystal violet absorption was
measured at 590 nm (Molecular Devices Co., Sunnyvale, CA, U.S.A.).
11. (a) Hosoi, J.; Abe, E.; Suda, T.; Kuroki, T. Cancer Res. 1985, 45, 1474; (b) Cho, Y.;
Kim, K.-H.; Shim, J.-S.; Hwang, J.-K. Biol. Pharm. Bull. 2008, 31, 986.
12. Dooley, T. P.; Gadwood, R. C.; Kilgore, K.; Thomasco, L. M. Skin Pharmacol. 1994,
7, 188.
resorcinol
Compound 1
6a (2,4-OH)
6b (3,5-OH)
6c (2,5-OH)
6d (3,4-OH)
6e (2,3-OH)
Hydroquinone
0.90
8.82
34.15
12.47
9.82
1.25
0.73
3.97
91.73 (20
99.24 (50
91.33 (30
99.10 (20
95.23 (30
96.17 (20
87.27 (10
lM)
lM)
lM)
lM)
lM)
lM)
lM)
>200
>200
>200
>200
>200
9.81
a
Values were determined from logarithmic concentration-inhibition curves and
are given as means of three experiments.